Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection

RecruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

December 31, 2040

Study Completion Date

December 31, 2040

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

Chimeric Antigen Receptor

CAR-T

Trial Locations (1)

RECRUITING

Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER